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OBJECTIVES: To determine whether cranberry capsules
prevent urinary tract infection (UTI) in long-term care
facility (LTCF) residents.
DESIGN: Double-blind randomized placebo-controlled mul-
ticenter trial.
SETTING: Long-term care facilities (LTCFs).
PARTICIPANTS: LTCF residents (N = 928; 703 women,
median age 84).
MEASUREMENTS: Cranberry and placebo capsules were
taken twice daily for 12 months. Participants were strati-
fied according to UTI risk (risk factors included long-term
catheterization, diabetes mellitus, ≥1 UTI in preceding
year). Main outcomes were incidence of UTI according to
a clinical definition and a strict definition.
RESULTS: In participants with high UTI risk at baseline
(n = 516), the incidence of clinically defined UTI was
lower with cranberry capsules than with placebo (62.8 vs
84.8 per 100 person-years at risk, P = .04); the treatment
effect was 0.74 (95% confidence interval (CI) = 0.57–
0.97). For the strict definition, the treatment effect was
1.02 (95% CI = 0.68–1.55). No difference in UTI inci-
dence between cranberry and placebo was found in partici-
pants with low UTI risk (n = 412).
CONCLUSION: In LTCF residents with high UTI risk at
baseline, taking cranberry capsules twice daily reduces the
incidence of clinically defined UTI, although it does not
reduce the incidence of strictly defined UTI. No difference
in incidence of UTI was found in residents with low UTI
risk. J Am Geriatr Soc 62:103–110, 2014.
Key words: geriatrics; long-term care facility; urinary
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Urinary tract infection (UTI) is a common bacterialinfection in residents of long-term care facilities
(LTCF),1,2 accounting for nearly 25% of all infections.3,4
UTI not only causes several days of illness, but may have
more-severe consequences such as delirium, dehydration,
urosepsis, hospitalization, or even death.5,6
Interventions to prevent UTI could reduce these severe
consequences,7 but there are no evidence-based interven-
tions that decrease UTI in institutionalized populations.1
The use of prophylactic antibiotics is currently controversial
because of side-effects and antibiotic resistance.8,9 Prophy-
laxis with cranberry is a potential prevention strategy.10,11
Cranberries contain proanthocyanidins (PACs), which are
stable phenolic compounds with anti-adhesion activity
against Escherichia coli.12–14 In vitro, antibacterial activity
of concentrated cranberry juice against other pathogens such
Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella
pneumoniae, and Proteus mirabilis has also been demon-
strated.15,16
There is aggregated evidence that cranberry juice may
lead to a decrease in the incidence of symptomatic UTIs
over a 12-month period, particularly in women with
recurrent UTIs.17,18 Another recent systematic review indi-
cates that cranberry-containing products are associated
with a protective effect against UTI in different sub-
groups, albeit with heterogeneity across the included tri-
als.19 A recent study in children without urological
abnormalities showed a 65% reduction of UTI with the
use of cranberry.20
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Two studies reported that cranberry juice may be
protective in subgroups of older adults,21,22 but the effec-
tiveness of cranberry capsules in the protection against
UTI in vulnerable older persons in LTCFs has not been
studied.
The present study assessed the effectiveness of cran-
berry capsules in preventing UTI in vulnerable older per-
sons living in LTCFs. Research in an institutionalized
population is challenging, and clinical manifestations of
UTI may be subtle.23–25 To be relevant for clinical practice
and science, a clinical definition according to international
guidelines for LTCF residents and a strict definition
according to scientific criteria were both used.
METHODS
Design
This was a double-blind randomized placebo-controlled
multicenter trial in two strata, based on baseline UTI risk.
Twenty-one LTCF organizations from the University Nurs-
ing Home Research Network in South Holland, the Neth-
erlands, participated.
The medical ethics committee of the Leiden University
Medical Center approved the study. Written informed con-
sent was obtained from all participants. A guardian pro-
vided written consent for participants incapable of giving
informed consent because of cognitive impairment.
Study Participants
LTCF residents aged 65 and older were included. Exclu-
sion criteria were use of coumarin and a life expectancy of
1 month or less. Coumarin users were excluded because of
a possible interaction between coumarin and cranberry,
leading to higher international normalized ratios and
bleeding.26–28
After informed consent and before randomization,
medical records were studied to stratify participants
according to baseline UTI risk. Participants with long-term
catheterization (>1 month), diabetes mellitus, or at least
one UTI in the preceding year were considered to be at
high UTI risk.
Within two strata of UTI risk, participants were ran-
domized into the cranberry or placebo group. Block ran-
domization (blocks of 6) was used, stratified for risk
profile and ability to give informed consent, generated
using a computer random number generator. Participants,
family, nursing staff, physicians, pharmacists, and research
nurses were blinded to treatment, and the random num-
bers were put in sealed envelopes so the research nurse
could allocate to the treatment group (cranberry or pla-
cebo) directly on the ward. Only the supplier of the cap-
sules knew the codes given to the capsules (cranberry or
placebo).
Intervention
Participants were randomly assigned to take cranberry or
placebo capsules twice daily for 12 months. Participants
already using a cranberry supplement stopped using their
own cranberry products before randomization and changed
to the study capsule at baseline. The cranberry capsules
contain 500 mg of the product, with 1.8% proanthocyani-
dins (9 mg). The placebo was indistinguishable in color,
taste, and appearance, consisting of cellulose microcrystal
colored red with azorubin.
The physician prescribed the coded capsules, and the
pharmacist added them to the drug-dispensing systems.
Nurses distributed the capsules and recorded whether the
participant took them on a drug kardex. Adherence was
measured over 1 month by counting all capsules that the
participants took during the fifth month of intervention
and comparing that with the prescribed number of
capsules.
Outcome Measures
The primary outcome was incidence of UTI. There is no
criterion standard in diagnosing UTI in LTCF residents.
Most clinical criteria to ascertain UTI are based on con-
sensus.29–31 A recent study showed that micturition-related
signs and symptoms are predictive of UTI.32
Because of the absence of a criterion standard in the
study population, this study used a clinical definition and
a strict UTI definition. The clinical definition of UTI is a
broad and practical definition following clinical practice
guidelines for LTCF residents.24,25 This clinical definition
of UTI is based on the presence of a minimum of one of
the following characteristics: specific and nonspecific mic-
turition-related symptoms and signs, a positive test (nitrite
test, leukocyte esterase test, dipslide, or culture), antibi-
otic treatment for UTI, or UTI reported in the medical
record.
Specific symptoms and signs are pain before, during,
or after micturition; increased frequency of micturition;
pain in abdomen; hematuria; foul smell; and signs of com-
mon sickness (fever >37.9°C or 1.5°C above baseline tem-
perature, chills, nausea, vomiting). Nonspecific symptoms
are anorexia, fatigue and reduced mobility, and signs of
delirium (e.g., confusion, deterioration in mental or func-
tional status).
The strict UTI definition is based on a scientific
approach, including the presence of micturition-related
symptoms and signs confirmed with a positive dipslide or
culture. A urine dipslide or culture was considered to be
positive when there were 105 CFU/mL or more bacteria,
with no more than two species of organisms present.
The treating physicians diagnosed the UTI and
reported the presence of UTI in the medical record. For
this study, they reported the needed study information on
a prestructured case report form, including presence of
specific and nonspecific micturition-related signs and symp-
toms, kind of testing and results, and antibiotic treatment.
Secondary outcomes were incidence of recurrent UTI,
hospitalization, and mortality.
In a companion cost-effectiveness article, whether the
effectiveness of cranberry capsule use is attained at reason-
able costs was investigated.33
At 6 and 12 months, a research nurse visited all par-
ticipants in their LTCF to check their medical records for
the occurrence of UTIs and to verify that all UTIs were
collected during the study period. Side effects and reasons
for withdrawal from the study were registered.
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Additional Measurements at Baseline
A research nurse interviewed all participants at baseline
in their LTCF, where face-to-face interviews were con-
ducted. If participants were not able to answer, their
responsible nurse was interviewed. Information on partici-
pant sociodemographic characteristics and medical history
were obtained at baseline. Care dependency was assessed
using the Care Dependency Scale (CDS),34 which measures
15 items of basic care needs on an aggregate scale from 15
to 75.
Sample Size
Sample size was based on an expected incidence of 44 first
UTIs per 100 residents per year in the placebo group. To
demonstrate a 40% reduction in incidence of UTI with the
use of cranberries,22 500 residents needed to be included
in each stratum (2 strata of 2 groups of 250)—1,000 resi-
dents in total (dropout rate 10%, alpha 0.05, power
80%).
Statistical Analysis
Differences in baseline characteristics between treatment
groups were compared using the Student t-test for continu-
ous variables and chi-square for categorical variables. The
incidence of UTI was calculated using the life-table
method. The number of first UTIs was assigned to the
numerator and the number of observed person-years at
risk was assigned to the denominator. The observed per-
son-years at risk were counted from randomization to end
of study, to date of death, or to date of first UTI. The
cumulative incidence of UTI for cranberry and placebo
was calculated accounting for mortality as competing
risk.35 The difference in the cumulative incidence of UTI
in residents between cranberry and placebo was tested
using the log-rank test. The treatment effect of cranberry
with respect to placebo was investigated using Cox pro-
portional hazards models, expressed as hazard ratios
(HRs).
The number needed to treat (NNT) was calculated
over 1 year of follow-up, based on the difference in pro-
portion of being event free in the placebo and cranberry
group.36,37 The difference in NNT between treatment
groups was tested using a z-test; P ≤ .05 was considered
significant.
To investigate possible heterogeneity in UTI rates
between individuals, a gamma-frailty model was fitted,38 a
random effect model for time-to-event data in which the
random effect (frailty) has a multiplicative effect on base-
line hazard function. Analyses were performed based on
intention to treat using SPSS for Windows version 17.0
(SPSS Inc., Chicago, IL) and R version 2.13.0 (R Founda-
tion for Statistical Computing, Vienna, Austria).
RESULTS
Between November 2008 and August 2009, all 2,086 eligi-
ble residents were invited to participate in a letter, and then
a research nurse orally invited them. The study stopped in
June 2011. Twenty-seven of the 955 residents who gave
written informed consent died before randomization,
resulting in a study population of 928 participants (Fig-
ure 1). A nonresponder analysis for giving informed con-
sent showed no difference between nonresponders and
responders in age, sex, or UTI risk profile. None of the
participants had end-stage renal disease.
Four hundred twelve low-UTI-risk and 516 high-UTI
risk-participants were included. There were no baseline
differences within the UTI risk groups between the cran-
berry and placebo groups (Table 1). Mean capsule intake
was 97% (95% confidence interval (CI) = 96.6–97.6%)
and was similar between the randomization groups and
between the risk groups.
Incidence of UTI
In the high-UTI-risk group, the curve of cumulative inci-
dence of clinically defined UTI showed a positive treatment
effect from 2 months of follow-up onward (P = .03). No
such effect was found for strictly defined UTI (P = .91).
There was no difference between cranberry and placebo in
the low-UTI-risk group (Figure 2).
In the high-UTI-risk group, the incidence of UTI
according to the clinical definition was 62.8 per 100 per-
son-years at risk (95% CI = 50.3–75.2) for cranberry and
84.8 per 100 person-years at risk (95% CI = 70.0–99.7)
for placebo (P = .04). The treatment effect in those at high
UTI risk was 0.74 (95% CI = 0.57–0.97). The incidence
for UTI following the strict definition was not different in
those using cranberry and placebo. The treatment effect
was 1.02 (95% CI = 0.68–1.55; Table 2). A subanalysis in
participants without long-term catheters in the high-UTI-
risk group (n = 420) showed a larger treatment effect of
cranberry capsules than of placebo for clinically defined
UTI (Table 2). According to the clinical definition, five
high-risk residents need to be treated with cranberry for
1 year to prevent one resident free of UTI for 1 year
(P = .01).
In the low-UTI-risk group, the incidence of UTI
according to the clinical definition was 40.3 per 100 per-
son-years at risk (95% CI = 30.0–50.5) for cranberry and
33.4 per 100 person-years at risk (95% CI = 24.2–42.5)
for placebo (P = .30).
Recurrent UTI
In a gamma-frailty model (a random effect model) using
all recurrent clinical UTIs, cranberry did not significantly
reduce the UTI rate in the high-UTI-risk group
(HR = 0.92, 95% CI = 0.71–1.17, frailty variance 0.62,
P < .001). In the low-UTI-risk group, the HR of cranberry
versus placebo was 1.14 (95% CI = 0.78–1.68, frailty
variance 1.50, P < .001).
Hospitalization and Mortality
Five participants (0.5%), all from the high-UTI-risk group,
were hospitalized during follow-up for UTI, with no
difference between cranberry and placebo (P = .62). In the
low-UTI-risk group, 114 (27.7%) participants died during
follow-up, of whom three died from UTI (cranberry vs pla-
cebo P = .56). In the high-UTI-risk group, 181 participants
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(35.1%) died during follow-up, of whom 14 (7.7%) died
from UTI, with no difference between cranberry and pla-
cebo (7 vs 7 P = .91).
DISCUSSION
This double-blind randomized placebo-controlled multi-
center trial investigated the effectiveness of cranberry cap-
sules to prevent UTI in older LTCF residents. In
participants with high UTI risk, twice-daily intake of cran-
berry capsules resulted in a 26% lower incidence of clini-
cally defined UTI than placebo, but no difference was
found in UTI incidence of strictly defined UTI. In residents
with low UTI risk, twice-daily intake of cranberry capsules
did not result in a lower incidence of UTI than with pla-
cebo.
Effectiveness
A systematic review showed that cranberry-containing
products were associated with a protective effect against
UTI in certain populations.19 A Cochrane review reported
a UTI reduction of 35% (95% CI = 10–54%).17 In the
recent update of this Cochrane review in 2012, the authors
performed a meta-analysis based on two studies evaluating
cranberry in elderly adults (N = 413).18 Cranberry did not
significantly reduce UTI in this population (risk
ratio = 0.75, 95% CI = 0.39–1.44).18 In contrast with this
last review, the current study found a positive effect of
treatment with cranberry capsules on the incidence of clin-
ically diagnosed UTI in 516 older persons with high UTI
risk. A possible explanation for this difference could be
the product used (juice vs capsules), study population (hos-
pitalized vs institutionalized), and sample size. Another
study comparing cranberry with low-dose trimethoprim
(follow-up 6 months) showed no difference between
cranberry and low-dose antibiotics but did not include a
placebo arm.39
It could have been expected that the beneficial effect
of cranberry capsules would be fairly prompt after start-
ing treatment, but the current study showed a beneficial
effect of cranberry capsules in the high-UTI-risk group
starting from 2 months of treatment on for clinically
defined UTI. This was shown in an earlier study that
found a reduction that started between 1 and 2 months
after initiating cranberry juice and remained stable
throughout the 6 months of follow-up.21 Cranberries with
PAC were expected to have an effect by different mecha-
nisms, because they influence the adhesive capacity of fi-
mbriae of bacteria and build a biofilm on the surface,
preventing adhesion. Nevertheless, bacteria could be per-
sistent (chronic bacteriuria), and the types of bacteria
could vary over time. So cranberry protects against UTI,
but it takes some time to have an effect.
Figure 1. Participant recruitment and follow-up. aDiabetes mellitus or urinary catheter or treated urinary tract infection in past
12 months. bNo adherence, withdrawn by elderly care physician or family. cIntervention stopped because of end of the study per-
iod. UTI = urinary tract infection.
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Because the effect of preventive care depends on the
incidence of the disease, a preplanned stratification was
made at baseline on baseline UTI risk. Based on the litera-
ture, LTCF residents with diabetes mellitus,40–42 long-term
catheterization,24,43,44 or UTI in the preceding year3,42,45,46
were considered to be at high risk. Although a group of
LTCF residents with a high incidence were selected using
these criteria, it might be that other criteria would have
selected a group with even higher risks or more prevent-
able UTIs.
Strengths and Limitations
This is the first large study of the effectiveness of cranberry
capsules in preventing UTI in LTCF residents. These resi-
dents represent a vulnerable older population, with a med-
ian age of 85 and older, severely dependent on care, high
infection rates, high levels of comorbidity, and 1-year mor-
tality of 35%47—a population in which clinical manifesta-
tions of UTI may be subtle.23
The current study was performed in Dutch LTCFs
—intramural care settings where elderly care physicians
provided medical care.48–53 Medication prescription and
distribution are well organized. The study capsules were
added to the existing drug-dispensing system. Medication
distribution by nurses is routine in Dutch LTCFs, and par-
ticipants rarely missed taking any capsule, which was
reflected in a high adherence rate, although adherence was
assessed only in the fifth month, which might not be gener-
alizable to the other months. This high and similar level of
adherence in both treatment groups also suggests that cap-
sules were well tolerated, side-effects were negligible, and
blinding remained adequate during the study.
A technical assessment of blinding was not performed,
although the research nurses did not receive information
about deblinding during the study visits. In addition, the
distribution and adherence of participants in the cranberry
and placebo groups were similar.
The clinical definition for UTI is based on a broad def-
inition of UTI (symptoms and signs, positive test, antibi-
otic treatment, or reported in the medical record) and
relies on the clinical judgment of the elderly care physi-
cian, in accordance with international clinical guidelines
for UTIs in LTCFs.24,25 Although this UTI definition is dif-
ferent from the strict definition, it reflects clinical care in
LTCFs and adds knowledge to practice guidelines to assist
physicians in making decisions.
The strict definition of UTI is based on a scientific
approach, including micturition-related symptoms and
signs confirmed according to a positive culture or dipslide,
and could be used for comparisons with studies in other
populations but is difficult to generalize to clinical practice
in LTCFs. It is generally accepted that diagnosing UTI in
vulnerable older persons, especially in long-term care, is
Table 1. Baseline Characteristics of Study Population at Randomization (Intention-to-Treat Analysis)
Characteristic
Low UTI Risk, n = 412 High UTI Risk, n = 516a
Cranberry, n = 205 Placebo, n = 207 Cranberry, n = 253 Placebo, n = 263
Sociodemographic
Female, n/N (%) 143/205 (69.8) 159/207 (76.8) 188/253 (74.3) 213/263 (81.0)
Age, n, median (IQR) 205, 84.0 (78.5–88.5) 207, 83.0 (79.0–88.0) 253, 85.0 (79.0–89.0) 263, 84.0 (79.0–88.0)
Length of stay, months, n, median (IQR) 204, 18.0 (4.0–42.0) 205, 19.0 (4.0–39.0) 251, 17.0 (6.0–41.0) 263, 19.0 (6.0–39.0)
Family informed consent, n/N (%) 180/205 (87.8) 185/207 (89.4) 205/253 (81.0) 212/263 (80.6)
Functioning
15-item Care Dependency Scale score
(range 15–75), n, median (IQR)
199, 42.0 (30.0–56.0) 197, 45.0 (30.5–55.0) 244, 44.0 (31.0–56.0) 250, 43.0 (30.0–56.0)
Cranberry use before start of study,
n/N (%)
3/196 (1.5) 6/202 (3.0) 18/248 (7.3) 22/253 (8.7)
Urinary incontinence, n/N (%) 138/198 (69.7) 136/199 (68.3) 152/247 (61.5) 157/246 (63.8)
Urinary catheter, n/N (%) 0/205 (0.0) 0/207 (0.0) 49/253 (19.4) 47/263 (17.9)
Infections in past 12 months
Urinary tract infection, n/N (%) 0/205 (0.0) 0/207 (0.0) 203/253 (80.2) 200/263 (76.0)
Number of UTIs in past 12 months, n,
median (IQR)
– – 202, 1.0 (1.0–2.0) 199, 2.0 (1.0–2.0)
Antibiotics for UTI suppression, n/N (%) 0/196 (0.0) 1/202 (0.5) 3/248 (1.2) 5/253 (2.0)
Lower respiratory tract infection, n/N (%) 35/200 (17.5) 35/204 (17.2) 47/249 (18.9) 54/259 (20.8)
Other infection, n/N (%) 21/200 (10.5) 24/204 (11.8) 38/248 (15.3) 33/255 (12.9)
Comorbidities, n/N (%)
Renal dysfunction 20/201 (10.0) 16/206 (7.8) 37/252 (14.7) 34/262 (13.0)
Urogenital surgery 40/200 (20.0) 45/203 (22.2) 50/253 (19.8) 66/262 (25.2)
Myocardial infarction 14/203 (6.9) 17/205 (8.3) 25/252 (9.9) 25/262 (9.5)
Stroke 38/204 (18.6) 33/205 (16.1) 64/251 (25.5) 76/261 (29.1)
Cancer 38/202 (18.8) 42/203 (20.7) 42/252 (16.7) 48/259 (18.5)
Diabetes mellitus 0/205 (0.0) 0/207 (0.0) 79/253 (31.2) 103/263 (39.2)
Chronic obstructive pulmonary disease 36/203 (17.7) 26/199 (13.1) 40/250 (16.0) 32/256 (12.5)
Dementia 162/199 (81.4) 177/207 (85.5) 174/250 (69.6) 187/261 (71.6)
IQR = interquartile range; UTI = urinary tract infection.
aDiabetes mellitus or urinary catheter or treated urinary tract infection in past 12 months.
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complicated. A recent study in nursing home residents
with advanced dementia showed that symptoms and signs
of UTI are frequently not present in older persons with
dementia.51 In the current study, for example, most partic-
ipants had dementia (76%) or incontinence (64%). There-
fore, a clean catch urine sample for culturing is often not
available, making it impossible to diagnose UTI according
to the strictest criteria.52 The current study was double-
blinded, so the randomization itself cannot have influenced
the clinical definition. Despite the large study sample, no
treatment effect was shown in those at high UTI risk using
the strict definition. The study may have been slightly
underpowered for the rarer strictly defined UTIs.
The optimum dosage of cranberries is not clear, and a
well-designed dose-finding study is needed. An in vitro
study suggests that the administration of 72 mg of PAC
daily may offer some protection against bacterial adhesion
in the bladder.53 The daily use of 18 mg of PAC (two cap-
sules) in this study may not have been high enough.
These results are not automatically generalizable to
vulnerable older persons living at home. Differences not
only in vulnerability and infection rates, but also in adher-
ence and hospitalization rates were expected.
CONCLUSIONS
In LTCF residents with high UTI risk, taking cranberry
capsules twice daily results in a 26% lower incidence of
clinically defined UTI than with placebo, although no dif-
ference was found in UTI incidence according to a strict
Low UTI-risk group  (cranberry  n = 205; placebo  n = 207)
High UTI-risk  group (cranberry  n = 253; placebo  n = 263)
Figure 2. Cumulative incidence of urinary tract infection (UTI) within 1 year of follow-up depending on treatment (cranberry or
placebo) stratified for those at low and high UTI risk, accounting for mortality as competing risk. Solid line: cranberry group;
dotted line: placebo group. Clinical definition: symptom or positive testing (nitrite test, leukocyte esterase test, dipslide or culture)
or antibiotic treatment or UTI reported in the medical record. Strict definition: symptom and positive dipslide or culture.
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definition. Cranberry capsules may offer an opportunity to
decrease the incidence of this common infection in high-
UTI-risk LTCF residents by using a well-tolerated treat-
ment.
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